tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2024 Mar 12:130820.
doi: 10.1016/j.ijbiomac.2024.130820. Online ahead of print. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants
Weiqi Wang[SUP] 1 [/SUP], Xianyong Meng[SUP] 2 [/SUP], Huan Cui[SUP] 3 [/SUP], Cheng Zhang[SUP] 3 [/SUP], Shen Wang[SUP] 4 [/SUP], Na Feng[SUP] 4 [/SUP], Yongkun Zhao[SUP] 4 [/SUP], Tiecheng Wang[SUP] 4 [/SUP], Feihu Yan[SUP] 5 [/SUP], Xianzhu Xia[SUP] 6 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants has resulted in global economic losses and posed a threat to human health. The pandemic highlights the urgent need for an efficient, easily producible, and broad-spectrum vaccine. Here, we present a potentially universal strategy for the rapid and general design of vaccines, focusing on the design and testing of omicron BA.5 RBD-conjugated self-assembling ferritin nanoparticles (NPs). The covalent bonding of RBD-Fc to protein A-ferritin was easily accomplished through incubation, resulting in fully multivalent RBD-conjugated NPs that exhibited high structural uniformity, stability, and efficient assembly. The ferritin nanoparticle vaccine synergistically stimulated the innate immune response, TFH-GCB-plasma cell-mediated activation of humoral immunity and IFNγ-driven cellular immunity. This nanoparticle vaccine induced a high level of cross-neutralizing responses and protected golden hamsters challenged with multiple mutant strains from infection-induced clinical disease, providing a promising strategy for broad-spectrum vaccine development for SARS-CoV-2 prophylaxis. In conclusion, the nanoparticle conjugation platform holds promise for its potential universality and competitive immunization efficacy and is expected to facilitate the rapid manufacturing and broad application of next-generation vaccines.
Keywords: Cross-neutralizing antibody; Nanoparticle vaccine; SARS-CoV-2; Self-assembled ferritin.
. 2024 Mar 12:130820.
doi: 10.1016/j.ijbiomac.2024.130820. Online ahead of print. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants
Weiqi Wang[SUP] 1 [/SUP], Xianyong Meng[SUP] 2 [/SUP], Huan Cui[SUP] 3 [/SUP], Cheng Zhang[SUP] 3 [/SUP], Shen Wang[SUP] 4 [/SUP], Na Feng[SUP] 4 [/SUP], Yongkun Zhao[SUP] 4 [/SUP], Tiecheng Wang[SUP] 4 [/SUP], Feihu Yan[SUP] 5 [/SUP], Xianzhu Xia[SUP] 6 [/SUP]
Affiliations
- PMID: 38484812
- DOI: 10.1016/j.ijbiomac.2024.130820
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants has resulted in global economic losses and posed a threat to human health. The pandemic highlights the urgent need for an efficient, easily producible, and broad-spectrum vaccine. Here, we present a potentially universal strategy for the rapid and general design of vaccines, focusing on the design and testing of omicron BA.5 RBD-conjugated self-assembling ferritin nanoparticles (NPs). The covalent bonding of RBD-Fc to protein A-ferritin was easily accomplished through incubation, resulting in fully multivalent RBD-conjugated NPs that exhibited high structural uniformity, stability, and efficient assembly. The ferritin nanoparticle vaccine synergistically stimulated the innate immune response, TFH-GCB-plasma cell-mediated activation of humoral immunity and IFNγ-driven cellular immunity. This nanoparticle vaccine induced a high level of cross-neutralizing responses and protected golden hamsters challenged with multiple mutant strains from infection-induced clinical disease, providing a promising strategy for broad-spectrum vaccine development for SARS-CoV-2 prophylaxis. In conclusion, the nanoparticle conjugation platform holds promise for its potential universality and competitive immunization efficacy and is expected to facilitate the rapid manufacturing and broad application of next-generation vaccines.
Keywords: Cross-neutralizing antibody; Nanoparticle vaccine; SARS-CoV-2; Self-assembled ferritin.